Wells Fargo analyst Steve Baxter maintained a Buy rating on Humana (HUM – Research Report) yesterday and set a price target of $350.00. The company’s shares closed last Friday at $312.59.
Baxter covers the Healthcare sector, focusing on stocks such as Humana, Elevance Health, and Molina Healthcare. According to TipRanks, Baxter has an average return of -1.0% and a 41.01% success rate on recommended stocks.
In addition to Wells Fargo, Humana also received a Buy from Goldman Sachs’s Nathan Rich in a report issued on April 8. However, on April 11, J.P. Morgan maintained a Hold rating on Humana (NYSE: HUM).
The company has a one-year high of $536.74 and a one-year low of $299.23. Currently, Humana has an average volume of 2.1M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana (HUM) Company Description:
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
